サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1761089

創薬技術の世界市場

Drug Discovery Technologies

出版日
ページ情報
英文 486 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.09円
創薬技術の世界市場
出版日: 2025年07月02日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 486 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

創薬技術の世界市場は2030年までに米国で1,242億米ドルに達する見込み

2024年に754億米ドルと推定される創薬技術の世界市場は、分析期間2024-2030年にCAGR 8.7%で成長し、2030年には1,242億米ドルに達すると予測されます。本レポートで分析したセグメントの一つである低分子医薬品は、CAGR 8.4%を記録し、分析期間終了時には927億米ドルに達すると予想されます。生物製剤セグメントの成長率は、分析期間中CAGR 9.6%と推定されます。

米国市場は202億米ドルと推定、中国はCAGR 10.6%で成長予測

米国の創薬技術市場は、2024年に202億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに190億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは10.6％となります。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ7.7%と7.3%と予測されています。欧州では、ドイツがCAGR約8.2%で成長すると予測されています。

世界の創薬技術市場- 主要動向と促進要因まとめ

創薬技術とは何か？

創薬技術は、新薬の同定と開発に使用される幅広い手法とツールで構成されています。これらの技術は、次世代の医薬品となる可能性のある新規化合物の発見と最適化のプロセスを合理化するため、製薬業界において非常に重要です。主要な技術には、ハイスループットスクリーニング（HTS）、ゲノミクス、プロテオミクス、バイオインフォマティクス、人工知能（AI）などがあります。HTSにより、研究者は何百万もの化学的、遺伝学的、薬理学的試験を迅速に実施することができ、実用的な医薬品につながる活性化合物の発見を劇的に早めることができます。ゲノミクスとプロテオミクスは、疾患に関連する遺伝子やタンパク質の発現に関する洞察を提供し、薬物療法の新たなターゲットを提供します。

人工知能はどのように創薬を変えるのか？

人工知能（AI）は、前例のないデータ処理能力と予測力を提供することで、創薬プロセスに革命をもたらしています。AIアルゴリズムは、医薬品臨床試験、患者記録、遺伝子情報などの膨大なデータセットを分析し、従来の方法に比べてわずかな時間とコストで、より高い精度で潜在的な医薬品候補を特定することができます。機械学習モデルは特に、データ中の複雑なパターンを認識し、異なる化学物質が人体とどのように相互作用するかを予測し、有効性を高め副作用を減らすために化学構造に修正を加えることを提案することに長けています。AI技術が進化を続けるにつれ、創薬プロセスへの統合はますます不可欠となり、より的を絞った効果的な治療が可能になります。

新しい創薬技術の採用にはどのような課題と機会が存在するか？

創薬における先端技術の統合は、効果的な治療法の開発に大きな機会をもたらす一方で、課題ももたらします。ロボット工学やAIプラットフォームなどの新技術の高額なコストは、小規模な製薬会社や研究機関にとっては障壁となり得る。さらに、これらの技術によって生成される膨大な量のデータを管理・分析するには、データ管理インフラや熟練した人材への多額の投資が必要となります。こうした課題にもかかわらず、医薬品開発に関連する時間とコストを大幅に削減できる可能性があることは、継続的な投資の有力なインセンティブとなっています。新興市場もまた、こうした技術の価値を認めており、世界の採用の拡大につながっています。

創薬技術市場の成長の原動力は？

創薬技術市場の成長は、新たな治療に対する緊急のニーズ、技術の進歩、製薬会社や政府による研究開発への資金提供や投資の増加など、いくつかの要因によってもたらされます。慢性疾患や感染症の世界の増加により、効果的な医薬品の迅速かつ効率的な開発が求められています。新薬発見の能力と効率を高める技術の進歩は、このような健康上の課題に対応する上で極めて重要です。さらに、製薬業界が遺伝子プロファイルに合わせた精密医療に注力することで、従来の創薬の限界が押し広げられ、先端技術への需要がさらに高まっています。

セグメント

タイプ（低分子医薬品、生物製剤）、テクノロジー（ハイスループットスクリーニング、バイオチップ、バイオインフォマティクス、ファーマコゲノミクス・薬理遺伝学、ナノテクノロジー、その他テクノロジー）、エンドユーザー（研究機関、製薬会社、バイオテクノロジー企業、その他エンドユーザー）

調査対象企業の例（注目の合計129社）

  • Agilent Technologies, Inc.
  • Beckman Coulter, Inc.
  • Bio-Rad Laboratories, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Antares Pharma, Inc.
  • Ambrx, Inc.
  • ActivX Biosciences, Inc.
  • Alembic Pharmaceuticals Limited
  • BioVision, Inc.
  • Acadia Pharmaceuticals, Inc.
  • Beactica Therapeutics AB
  • Atomwise, Inc.
  • BeiGene LTD.
  • ATXA Therapeutics
  • Bayer Pharmaceuticals

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオトランスクリプト、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中のドメインエキスパートからキュレートされたコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP-1506

Global Drug Discovery Technologies Market to Reach US$124.2 Billion by 2030

The global market for Drug Discovery Technologies estimated at US$75.4 Billion in the year 2024, is expected to reach US$124.2 Billion by 2030, growing at a CAGR of 8.7% over the analysis period 2024-2030. Small Molecule Drugs, one of the segments analyzed in the report, is expected to record a 8.4% CAGR and reach US$92.7 Billion by the end of the analysis period. Growth in the Biologics segment is estimated at 9.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$20.2 Billion While China is Forecast to Grow at 10.6% CAGR

The Drug Discovery Technologies market in the U.S. is estimated at US$20.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$19.0 Billion by the year 2030 trailing a CAGR of 10.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.7% and 7.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.2% CAGR.

Global Drug Discovery Technologies Market - Key Trends & Drivers Summarized

What Are Drug Discovery Technologies and How Do They Propel Pharmaceutical Innovation?

Drug discovery technologies comprise a broad range of methods and tools used in the identification and development of new therapeutic drugs. These technologies are critical in the pharmaceutical industry as they streamline the process of discovering and optimizing new compounds that may become the next generation of medications. Key technologies include high-throughput screening (HTS), genomics, proteomics, bioinformatics, and artificial intelligence (AI). HTS allows researchers to quickly conduct millions of chemical, genetic, or pharmacological tests, dramatically speeding up the discovery of active compounds that could lead to viable drugs. Genomics and proteomics provide insights into the genetic and protein expressions related to diseases, offering new targets for drug therapy.

How Is Artificial Intelligence Transforming Drug Discovery?

Artificial intelligence (AI) is revolutionizing the drug discovery process by offering unprecedented data processing capabilities and predictive power. AI algorithms can analyze vast datasets from drug trials, patient records, and genetic information to identify potential drug candidates with higher precision and at a fraction of the time and cost compared to traditional methods. Machine learning models are particularly adept at recognizing complex patterns in data, predicting how different chemicals will interact with the human body, and suggesting modifications to chemical structures to enhance efficacy and reduce side effects. As AI technology continues to evolve, its integration into drug discovery processes is becoming increasingly indispensable, enabling more targeted and effective therapies.

What Challenges and Opportunities Exist in the Adoption of New Drug Discovery Technologies?

While the integration of advanced technologies in drug discovery presents significant opportunities for the development of effective treatments, it also introduces challenges. The high cost of new technologies, such as robotics and AI platforms, can be a barrier for smaller pharmaceutical companies and research institutions. Additionally, managing and analyzing the enormous volumes of data generated by these technologies require substantial investments in data management infrastructure and skilled personnel. Despite these challenges, the potential to drastically reduce the time and cost associated with drug development is a compelling incentive for continued investment. Emerging markets are also recognizing the value of these technologies, leading to increased adoption worldwide.

What Drives the Growth in the Drug Discovery Technologies Market?

The growth in the drug discovery technologies market is driven by several factors, including the urgent need for new medical treatments, advancements in technology, and increased funding and investment in R&D by pharmaceutical companies and governments. The rising prevalence of chronic and infectious diseases worldwide demands faster and more efficient development of effective drugs. Technological advancements that offer enhanced capabilities and efficiencies in discovering new drugs are critical in meeting these health challenges. Additionally, the pharmaceutical industry's focus on precision medicine tailored to genetic profiles is pushing the boundaries of traditional drug discovery, further fueling the demand for advanced technologies.

SCOPE OF STUDY:

The report analyzes the Drug Discovery Technologies market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Small Molecule Drugs, Biologics); Technology (High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology, Other Technologies); End-Use (Research Institutes, Pharmaceutical Companies, Biotechnology Companies, Other End-Uses)

Geographic Regions/Countries:

World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Rest of Europe; Asia-Pacific; Rest of World.

Select Competitors (Total 129 Featured) -

  • Agilent Technologies, Inc.
  • Beckman Coulter, Inc.
  • Bio-Rad Laboratories, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Antares Pharma, Inc.
  • Ambrx, Inc.
  • ActivX Biosciences, Inc.
  • Alembic Pharmaceuticals Limited
  • BioVision, Inc.
  • Acadia Pharmaceuticals, Inc.
  • Beactica Therapeutics AB
  • Atomwise, Inc.
  • BeiGene LTD.
  • ATXA Therapeutics
  • Bayer Pharmaceuticals

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Drug Discovery Technologies - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
    • A Prelude to Drug Discovery Technologies
    • Global Market Analysis and Prospects
    • Global Drug Discovery Technologies Market Set to Witness Rapid Growth
    • Regional Market Analysis
    • Market Analysis based on Application
    • Market Analysis based on End-User
    • Competition
    • Recent Market Activity
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Late-Stage Drug Failures Drives Demand for Drug Discovery Technolgies
    • Factors Leading to Failure of Drugs in Phase III Clinical Trials: Percentage Breakdown of Number of Cases for Efficacy, Pharmacokinetics, Toxicity and Others
    • Cell-based Assays Play a Critical Role in Drug Discovery
    • Major Types of Cell-Based HTS Assays for Drug Screening
    • High-Content Screening (HCS) - An Expanding Technology in Cell-Based Assays
    • High Content Screening - Key Application Areas
    • Technology Advances in Drug Discovery Processes
    • Increased Demand of Biochips in Drug Discovery to Drive Market Growth
    • Increased Demand for Personalized Medicine to Drive Drug Discovery Technologies Market
    • Global Personalized Medicine Market: Revenues in US$ Million for the Years 2019, 2021, 2023 and 2025
    • Proteomics and Genomics Drive Opportunities for Drug Discovery Technologies
    • Proteomics Profiling to Expedite Drug Discovery
    • Other Applications of Proteomics in Drug Discovery
    • New Proteomics Technique to Aid Drug Screening & Biomarker Discovery
    • Proteomic Approaches Gain Prominence in Cancer Drug Discovery
    • Proteomics Technologies Used in Cancer Drug Discovery and Development
    • Role of Proteomics in Oncology Biomarker Discovery
    • Bioinformatics Tools along with Proteomics Accelerate the Process of Pathway Prediction
    • Using AI in Drug Discovery: The Latest Market Research
    • High-throughput Screening (HTS) - A Key Drug Discovery Technology
    • HTS: Making Use of a Smarter Approach to Hit Discovery
    • Emerging Technologies in Drug Discovery and Development
    • Targeted Drug Development and Discovery
    • Significance of Advanced Clinical Sequencing for Drug Developers
    • Metabolomics: An Emerging Trend in Drug Discovery
    • Impact of ADME-Tox Screening on New Drug Discovery
    • Phase-I Clinical Trial Failures Before and After the Advent of Preclinical ADME/Pharmacokinetics
    • Pharma Industry Renews Focus on Cost Optimization
    • China and India: Hot Spots for R&D Investment
    • Omics Technology to Witness Rapid Growth
    • Adoption of Omics-based Technologies
    • Increasing Demand for 3D Cell Culture in Drug Discovery
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Drug Discovery Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Drug Discovery Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 3: World 15-Year Perspective for Drug Discovery Technologies by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Small Molecule Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Small Molecule Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 6: World 15-Year Perspective for Small Molecule Drugs by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 9: World 15-Year Perspective for Biologics by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for High Throughput Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World Historic Review for High Throughput Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 12: World 15-Year Perspective for High Throughput Screening by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Biochips by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Biochips by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 15: World 15-Year Perspective for Biochips by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Bioinformatics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Bioinformatics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 18: World 15-Year Perspective for Bioinformatics by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Pharmacogenomics & Pharmacogenetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Pharmacogenomics & Pharmacogenetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 21: World 15-Year Perspective for Pharmacogenomics & Pharmacogenetics by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Nanotechnology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Nanotechnology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 24: World 15-Year Perspective for Nanotechnology by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 26: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 27: World 15-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 29: World Historic Review for Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 30: World 15-Year Perspective for Research Institutes by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 31: World Recent Past, Current & Future Analysis for Pharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 32: World Historic Review for Pharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 33: World 15-Year Perspective for Pharmaceutical Companies by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 34: World Recent Past, Current & Future Analysis for Biotechnology Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 35: World Historic Review for Biotechnology Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 36: World 15-Year Perspective for Biotechnology Companies by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 37: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 38: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 39: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 40: World Drug Discovery Technologies Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Drug Discovery Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 41: USA Recent Past, Current & Future Analysis for Drug Discovery Technologies by Type - Small Molecule Drugs and Biologics - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Drug Discovery Technologies by Type - Small Molecule Drugs and Biologics Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for Drug Discovery Technologies by Type - Percentage Breakdown of Value Revenues for Small Molecule Drugs and Biologics for the Years 2015, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Drug Discovery Technologies by Technology - High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Drug Discovery Technologies by Technology - High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: USA 15-Year Perspective for Drug Discovery Technologies by Technology - Percentage Breakdown of Value Revenues for High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Drug Discovery Technologies by End-Use - Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Drug Discovery Technologies by End-Use - Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: USA 15-Year Perspective for Drug Discovery Technologies by End-Use - Percentage Breakdown of Value Revenues for Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Drug Discovery Technologies by Type - Small Molecule Drugs and Biologics - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Drug Discovery Technologies by Type - Small Molecule Drugs and Biologics Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Canada 15-Year Perspective for Drug Discovery Technologies by Type - Percentage Breakdown of Value Revenues for Small Molecule Drugs and Biologics for the Years 2015, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Drug Discovery Technologies by Technology - High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Drug Discovery Technologies by Technology - High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Canada 15-Year Perspective for Drug Discovery Technologies by Technology - Percentage Breakdown of Value Revenues for High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Drug Discovery Technologies by End-Use - Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Drug Discovery Technologies by End-Use - Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Canada 15-Year Perspective for Drug Discovery Technologies by End-Use - Percentage Breakdown of Value Revenues for Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • Drug Discovery Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Drug Discovery Technologies by Type - Small Molecule Drugs and Biologics - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Drug Discovery Technologies by Type - Small Molecule Drugs and Biologics Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Japan 15-Year Perspective for Drug Discovery Technologies by Type - Percentage Breakdown of Value Revenues for Small Molecule Drugs and Biologics for the Years 2015, 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Drug Discovery Technologies by Technology - High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Drug Discovery Technologies by Technology - High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Japan 15-Year Perspective for Drug Discovery Technologies by Technology - Percentage Breakdown of Value Revenues for High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Drug Discovery Technologies by End-Use - Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Drug Discovery Technologies by End-Use - Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Japan 15-Year Perspective for Drug Discovery Technologies by End-Use - Percentage Breakdown of Value Revenues for Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • Drug Discovery Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 68: China Recent Past, Current & Future Analysis for Drug Discovery Technologies by Type - Small Molecule Drugs and Biologics - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Drug Discovery Technologies by Type - Small Molecule Drugs and Biologics Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: China 15-Year Perspective for Drug Discovery Technologies by Type - Percentage Breakdown of Value Revenues for Small Molecule Drugs and Biologics for the Years 2015, 2025 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Drug Discovery Technologies by Technology - High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Drug Discovery Technologies by Technology - High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: China 15-Year Perspective for Drug Discovery Technologies by Technology - Percentage Breakdown of Value Revenues for High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 74: China Recent Past, Current & Future Analysis for Drug Discovery Technologies by End-Use - Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Drug Discovery Technologies by End-Use - Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: China 15-Year Perspective for Drug Discovery Technologies by End-Use - Percentage Breakdown of Value Revenues for Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • Drug Discovery Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Drug Discovery Technologies by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Drug Discovery Technologies by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Drug Discovery Technologies by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Drug Discovery Technologies by Type - Small Molecule Drugs and Biologics - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Drug Discovery Technologies by Type - Small Molecule Drugs and Biologics Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Europe 15-Year Perspective for Drug Discovery Technologies by Type - Percentage Breakdown of Value Revenues for Small Molecule Drugs and Biologics for the Years 2015, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Drug Discovery Technologies by Technology - High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Drug Discovery Technologies by Technology - High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Europe 15-Year Perspective for Drug Discovery Technologies by Technology - Percentage Breakdown of Value Revenues for High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Drug Discovery Technologies by End-Use - Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Drug Discovery Technologies by End-Use - Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Europe 15-Year Perspective for Drug Discovery Technologies by End-Use - Percentage Breakdown of Value Revenues for Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • FRANCE
    • Drug Discovery Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 89: France Recent Past, Current & Future Analysis for Drug Discovery Technologies by Type - Small Molecule Drugs and Biologics - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Drug Discovery Technologies by Type - Small Molecule Drugs and Biologics Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: France 15-Year Perspective for Drug Discovery Technologies by Type - Percentage Breakdown of Value Revenues for Small Molecule Drugs and Biologics for the Years 2015, 2025 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Drug Discovery Technologies by Technology - High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Drug Discovery Technologies by Technology - High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: France 15-Year Perspective for Drug Discovery Technologies by Technology - Percentage Breakdown of Value Revenues for High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 95: France Recent Past, Current & Future Analysis for Drug Discovery Technologies by End-Use - Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Drug Discovery Technologies by End-Use - Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: France 15-Year Perspective for Drug Discovery Technologies by End-Use - Percentage Breakdown of Value Revenues for Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • Drug Discovery Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Drug Discovery Technologies by Type - Small Molecule Drugs and Biologics - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Drug Discovery Technologies by Type - Small Molecule Drugs and Biologics Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Germany 15-Year Perspective for Drug Discovery Technologies by Type - Percentage Breakdown of Value Revenues for Small Molecule Drugs and Biologics for the Years 2015, 2025 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Drug Discovery Technologies by Technology - High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Drug Discovery Technologies by Technology - High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Germany 15-Year Perspective for Drug Discovery Technologies by Technology - Percentage Breakdown of Value Revenues for High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Drug Discovery Technologies by End-Use - Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for Drug Discovery Technologies by End-Use - Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Germany 15-Year Perspective for Drug Discovery Technologies by End-Use - Percentage Breakdown of Value Revenues for Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Drug Discovery Technologies by Type - Small Molecule Drugs and Biologics - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Drug Discovery Technologies by Type - Small Molecule Drugs and Biologics Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Italy 15-Year Perspective for Drug Discovery Technologies by Type - Percentage Breakdown of Value Revenues for Small Molecule Drugs and Biologics for the Years 2015, 2025 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Drug Discovery Technologies by Technology - High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Drug Discovery Technologies by Technology - High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Italy 15-Year Perspective for Drug Discovery Technologies by Technology - Percentage Breakdown of Value Revenues for High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Drug Discovery Technologies by End-Use - Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for Drug Discovery Technologies by End-Use - Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Italy 15-Year Perspective for Drug Discovery Technologies by End-Use - Percentage Breakdown of Value Revenues for Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Drug Discovery Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 116: UK Recent Past, Current & Future Analysis for Drug Discovery Technologies by Type - Small Molecule Drugs and Biologics - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Drug Discovery Technologies by Type - Small Molecule Drugs and Biologics Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: UK 15-Year Perspective for Drug Discovery Technologies by Type - Percentage Breakdown of Value Revenues for Small Molecule Drugs and Biologics for the Years 2015, 2025 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Drug Discovery Technologies by Technology - High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Drug Discovery Technologies by Technology - High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: UK 15-Year Perspective for Drug Discovery Technologies by Technology - Percentage Breakdown of Value Revenues for High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 122: UK Recent Past, Current & Future Analysis for Drug Discovery Technologies by End-Use - Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for Drug Discovery Technologies by End-Use - Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: UK 15-Year Perspective for Drug Discovery Technologies by End-Use - Percentage Breakdown of Value Revenues for Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 125: Rest of Europe Recent Past, Current & Future Analysis for Drug Discovery Technologies by Type - Small Molecule Drugs and Biologics - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Europe Historic Review for Drug Discovery Technologies by Type - Small Molecule Drugs and Biologics Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Rest of Europe 15-Year Perspective for Drug Discovery Technologies by Type - Percentage Breakdown of Value Revenues for Small Molecule Drugs and Biologics for the Years 2015, 2025 & 2030
    • TABLE 128: Rest of Europe Recent Past, Current & Future Analysis for Drug Discovery Technologies by Technology - High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Europe Historic Review for Drug Discovery Technologies by Technology - High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of Europe 15-Year Perspective for Drug Discovery Technologies by Technology - Percentage Breakdown of Value Revenues for High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Drug Discovery Technologies by End-Use - Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Europe Historic Review for Drug Discovery Technologies by End-Use - Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Europe 15-Year Perspective for Drug Discovery Technologies by End-Use - Percentage Breakdown of Value Revenues for Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Drug Discovery Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 134: Asia-Pacific Recent Past, Current & Future Analysis for Drug Discovery Technologies by Type - Small Molecule Drugs and Biologics - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Asia-Pacific Historic Review for Drug Discovery Technologies by Type - Small Molecule Drugs and Biologics Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Asia-Pacific 15-Year Perspective for Drug Discovery Technologies by Type - Percentage Breakdown of Value Revenues for Small Molecule Drugs and Biologics for the Years 2015, 2025 & 2030
    • TABLE 137: Asia-Pacific Recent Past, Current & Future Analysis for Drug Discovery Technologies by Technology - High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Asia-Pacific Historic Review for Drug Discovery Technologies by Technology - High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Asia-Pacific 15-Year Perspective for Drug Discovery Technologies by Technology - Percentage Breakdown of Value Revenues for High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Drug Discovery Technologies by End-Use - Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Asia-Pacific Historic Review for Drug Discovery Technologies by End-Use - Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Asia-Pacific 15-Year Perspective for Drug Discovery Technologies by End-Use - Percentage Breakdown of Value Revenues for Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 143: Rest of World Recent Past, Current & Future Analysis for Drug Discovery Technologies by Type - Small Molecule Drugs and Biologics - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of World Historic Review for Drug Discovery Technologies by Type - Small Molecule Drugs and Biologics Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Rest of World 15-Year Perspective for Drug Discovery Technologies by Type - Percentage Breakdown of Value Revenues for Small Molecule Drugs and Biologics for the Years 2015, 2025 & 2030
    • TABLE 146: Rest of World Recent Past, Current & Future Analysis for Drug Discovery Technologies by Technology - High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of World Historic Review for Drug Discovery Technologies by Technology - High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Rest of World 15-Year Perspective for Drug Discovery Technologies by Technology - Percentage Breakdown of Value Revenues for High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 149: Rest of World Recent Past, Current & Future Analysis for Drug Discovery Technologies by End-Use - Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Rest of World Historic Review for Drug Discovery Technologies by End-Use - Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Rest of World 15-Year Perspective for Drug Discovery Technologies by End-Use - Percentage Breakdown of Value Revenues for Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION